CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 128 filers reported holding CRINETICS PHARMACEUTICALS IN in Q1 2023. The put-call ratio across all filers is 0.00 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $32,714,000 | +65.0% | 1,100,000 | 0.0% | 2.42% | +57.8% |
| Q2 2023 | $19,822,000 | +12.2% | 1,100,000 | 0.0% | 1.53% | +31.4% |
| Q1 2023 | $17,666,000 | +31.0% | 1,100,000 | +49.2% | 1.17% | +38.5% |
| Q4 2022 | $13,488,143 | +8.7% | 737,057 | +16.7% | 0.84% | +42.5% |
| Q3 2022 | $12,405,000 | +5.3% | 631,627 | 0.0% | 0.59% | +1.9% |
| Q2 2022 | $11,780,000 | +26.3% | 631,627 | +48.7% | 0.58% | +17.9% |
| Q1 2022 | $9,326,000 | +124.9% | 424,897 | +56.6% | 0.49% | +187.7% |
| Q1 2021 | $4,147,000 | +8.3% | 271,378 | 0.0% | 0.17% | +4.3% |
| Q4 2020 | $3,829,000 | -9.9% | 271,378 | 0.0% | 0.16% | -22.3% |
| Q3 2020 | $4,252,000 | +13.2% | 271,378 | +26.5% | 0.21% | -13.2% |
| Q2 2020 | $3,757,000 | +55.4% | 214,453 | +30.4% | 0.24% | +50.9% |
| Q1 2020 | $2,417,000 | -28.6% | 164,453 | +21.8% | 0.16% | -26.1% |
| Q4 2019 | $3,387,000 | +66.8% | 135,009 | 0.0% | 0.22% | -37.4% |
| Q3 2019 | $2,031,000 | -39.8% | 135,009 | 0.0% | 0.35% | -26.4% |
| Q2 2019 | $3,375,000 | +9.8% | 135,009 | 0.0% | 0.47% | +4.0% |
| Q1 2019 | $3,073,000 | -24.1% | 135,009 | 0.0% | 0.46% | -20.2% |
| Q4 2018 | $4,049,000 | -5.8% | 135,009 | -10.0% | 0.57% | +67.2% |
| Q3 2018 | $4,298,000 | – | 150,000 | – | 0.34% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 410,360 | $11,658,000 | 6.24% |
| 5AM Venture Management, LLC | 862,286 | $24,498,000 | 4.60% |
| Bain Capital Life Sciences Investors, LLC | 2,029,701 | $57,664,000 | 4.57% |
| Opaleye Management Inc. | 724,400 | $20,580,000 | 4.36% |
| Deep Track Capital, LP | 1,900,000 | $53,979,000 | 3.81% |
| BVF INC/IL | 3,003,879 | $85,340,000 | 3.10% |
| FRAZIER MANAGEMENT LLC | 1,384,293 | $39,328,000 | 3.03% |
| Altium Capital Management LP | 331,000 | $9,404,000 | 2.59% |
| Perceptive Advisors | 10,327,034 | $293,392,000 | 2.26% |
| MPM BioImpact LLC | 379,792 | $10,790,000 | 1.97% |